Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Auristatin E | Auristatin E is a synthetic analog of dolastatin 10. Auristatin E is a highly potent antimitotic agent.Auristatin E inhibits tubulin polymerization. Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity. Uses: Adcs cytotoxin. Synonyms: Auristatin E. Grade: ≥96.0% (HPLC). CAS No. 160800-57-7. Molecular formula: C40H69N5O7. Mole weight: 732.01. |  |
| Monomethyl auristatin E | Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MMAE; SGD-1010; Vedotin. CAS No. 474645-27-7. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-15162. |  |
| Monomethyl auristatin E (Standard) | Monomethyl auristatin E (MMAE) (Standard) is the analytical standard of Monomethyl auristatin E (HY-15162). This product is intended for research and analytical applications. Monomethyl auristatin E is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) against several different cancer types[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MMAE (Standard); SGD-1010 (Standard); Vedotin (Standard). CAS No. 474645-27-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15162R. | |
| Anetumab-MMAE | Anetumab-MMAE is an antibody-drug conjugate consisting of an anti-MSLN monoclonal antibody and monomethyl auristatin E (MMAE). MMAE is an antimitotic agent that inhibits tubulin polymerization. | |
| Brentuximab | Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC 50 of 10 nM against human CD30+ cancer cells [1] [2] [3]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 2088770-90-3. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99151. | |
| Cofetuzumab pelidotin | Cofetuzumab pelidotin (PF-06647020) is a PTK7 -targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC 50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research [1] [2] [3]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: PF-06647020; ABBV-647; h6M24-vc0101. CAS No. 1869937-48-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99829. | |
| Disitamab vedotin | Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RC48. CAS No. 2136633-23-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9985. | |
| Dov-Val-Dil-OH TFA | Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Dov-Val-Dil-OH TFA; Dov-Val-Dil-OH; Dov-Val-Dil-OH; dimethylVal-Val-Dil-COOH. Product Category: Others. Appearance: Solid powder. CAS No. 133120-90-8. Molecular formula: C24H44F3N3O7. Mole weight: 543.63. Purity: >98%. IUPACName: (3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoic acid trifluoroacetic acid. Canonical SMILES: CC[C@H](C)[C@H](N(C)C([C@@H](NC([C@@H](N(C)C)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(O)=O.O=C(O)C(F)(F)F. Product ID: ACM133120908. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Enfortumab vedotin-ejfv | Enfortumab vedotin-ejfv is a first-in-class monoclonal antibody drug conjugate that binds Nectin-4, a protein expressed on bladder cancer cells, and delivers the tubulin toxin, monomethyl auristatin E, into the cell causing cell death. Enfortumab vedotin-ejfv was approved by FDA for the treatment of locally advanced or metastatic urothelial cancer. Synonyms: Padcev. CAS No. 1346452-25-2. | |
| Fmoc-MMAE | Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE) and a potent tubulin inhibitor. Grade: 98%. CAS No. 474645-26-6. Molecular formula: C54H77N5O9. Mole weight: 940.22. | |
| Glembatumumab | Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling ( ADC ) with antitumor activity [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1020264-78-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99205. | |
| Glembatumumab | Glembatumumab is a human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be linked to monomethyl auristatin E (MMAE) to form Glembatumumab vedotin, an ADC for cancer therapy. Synonyms: Anti-GPNMB. CAS No. 1020264-78-1. | |
| Lifastuzumab | Lifastuzumab is a humanized anti- NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1615697-16-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99970. | |
| Mc-MMAE | Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Maleimidocaproyl-monomethylauristatin E. CAS No. 863971-24-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15741. | |
| MC-Val-Cit-PAB-MMAE | MC-Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate. Synonyms: VcMMAE; Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E; Vedotin. Grade: 95%. CAS No. 646502-53-6. Molecular formula: C68H105N11O15. Mole weight: 1316.63. | |
| MMAE | Monomethyl Auristatin E (MMAE) is a synthetic analog of dolastatin 10 that similarly inhibits tubulin polymerization and exhibits potent cytotoxicity. It is commonly conjugated with monoclonal antibodies directed at antigens specific to cancer cells for tumor-directed cytotoxicity. Uses: Adcs cytotoxin. Synonyms: MMAE; Vedotin; Monomethyl auristatin E; Monomethylauristatin E; N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide. Grade: ≥98.0% by HPLC. CAS No. 474645-27-7. Molecular formula: C39H67N5O7. Mole weight: 717.98. | |
| MMAE-d8 | MMAE-d 8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor. Uses: Scientific research. Group: Isotope-labeled compounds. Alternative Names: Monomethyl auristatin E-d8; Deuterated labeled MMAE. CAS No. 2070009-72-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-15162A. | |
| MMAE-[d8] | MMAE-[d8] is a labelled analogue of MMAE, which is a potent mitotic inhibitor and a tubulin inhibitor. Synonyms: D8-MMAE; D8-Monomethyl auristatin E. Grade: 98% by HPLC; 98% atom D. CAS No. 2070009-72-0. Molecular formula: C39H59D8N5O7. Mole weight: 726.03. | |
| MMAF | Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. Uses: Adcs cytotoxin. Synonyms: Monomethylauristatin F; Monomethyl Auristatin F; N-Methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine; Monomethylauristatin Phenylalanine; L-Valinamide, N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-; ((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine. Grade: ≥98% by HPLC. CAS No. 745017-94-1. Molecular formula: C39H65N5O8. Mole weight: 731.48. | |
| MMAF Hydrochloride | MMAF Hydrochloride, a synthetic antineoplastic agent, is a tubulin polymerization inhibitor that inhibits cell division by blocking the polymerization of tubulin. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. Uses: Adcs cytotoxin. Synonyms: Monomethylauristatin F Hydrochloride; Monomethyl Auristatin F Hydrochloride; N-Methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine Hydrochloride; Monomethylauristatin Phenylalanine Hydrochloride; L-Valinamide, N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-, Hydrochloride (1:1); ((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine Hydrochloride. Grade: >98%. CAS No. 1415246-68-2. Molecular formula: C39H66ClN5O8. Mole weight: 768.42. | |
| PF-06380101 | PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. Uses: Adcs cytotoxin. Synonyms: PF-06380101; PF 06380101; PF06380101; Auristatin 0101; AUR-0101; AUR 0101; AUR0101. Grade: >98%. CAS No. 1436391-86-4. Molecular formula: C39H62N6O6S. Mole weight: 743.01. | |
| Polatuzumab vedotin | Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1313206-42-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-132253. | |
| Polatuzumab vedotin (solution) | Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1313206-42-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-132253A. | |
| Telisotuzumab vedotin | Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate ( ADCs ) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ABBV-399. CAS No. 1714088-51-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-141601. | |
| Tert-Butyl 2-(methylamino)ethyl carbamate | tert-Butyl 2-(methylamino)ethylcarbamate is a useful research chemical used in the investigation of hydrophilic auristatin derivatives for use in antibody-drug conjugates. Synonyms: N-[2-(methylamino)ethyl]carbamic acid tert-butyl ester; N-(tert-Butoxycarbonyl)-N'-methylethylenediamine; N-(tert-Butoxycarbonyl)-N'-methyl-1,2-diaminoethane; N-Boc-N'-methylethylenediamine; N-(2-Methylaminoethyl)carbamic Acid tert-Butyl Ester. Grade: 95 % (GC). CAS No. 122734-32-1. Molecular formula: C8H18N2O2. Mole weight: 174.24. | |
| Tisotumab vedotin | Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1418731-10-8. Pack Sizes: 1 mg; 5 mg. Product ID: HY-152963. | |
| Trastuzumab vedotin | Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MRG002; Trastuzumab MMAE. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-164992. | |
| VcMMAE | VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Uses: Scientific research. Group: Signaling pathways. Alternative Names: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE. CAS No. 646502-53-6. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-15575. | |
Our database is helping our users find suppliers everyday.
